Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Up 75.3% in February

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) saw a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 4,750,000 shares, an increase of 75.3% from the January 31st total of 2,710,000 shares. Currently, 44.9% of the company’s shares are short sold. Based on an average daily trading volume, of 18,790,000 shares, the days-to-cover ratio is currently 0.3 days.

Hepion Pharmaceuticals Price Performance

HEPA stock opened at $0.09 on Tuesday. The firm has a market capitalization of $649,181.40, a P/E ratio of -0.02 and a beta of 1.65. Hepion Pharmaceuticals has a 52-week low of $0.10 and a 52-week high of $2.93. The company’s 50 day simple moving average is $0.31 and its 200-day simple moving average is $0.54.

Hedge Funds Weigh In On Hepion Pharmaceuticals

A hedge fund recently bought a new stake in Hepion Pharmaceuticals stock. Anson Funds Management LP bought a new position in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned 3.33% of Hepion Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 17.24% of the company’s stock.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.